BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urquiza M, Lopez R, Patiño H, Rosas JE, Patarroyo ME. Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells. Journal of Biological Chemistry 2005;280:35598-605. [DOI: 10.1074/jbc.m504544200] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhu C, Song H, Xu F, Yi W, Liu F, Liu X. Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo. Oncol Lett 2018;15:7459-63. [PMID: 29731897 DOI: 10.3892/ol.2018.8223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, Mayer B. Concept and application of a computational vaccinology workflow. Immunome Res 2010;6 Suppl 2:S7. [PMID: 21067549 DOI: 10.1186/1745-7580-6-S2-S7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
3 Zhang X, Zhao B, Ding M, Song S, Kang Y, Yu Y, Xu M, Xiang T, Gao L, Feng Q, Zhao Q, Zeng MS, Krummenacher C, Zeng YX. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics 2020;10:5704-18. [PMID: 32483413 DOI: 10.7150/thno.42494] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bingöl EN, Taştekil I, Yay C, Keskin N, Ozbek P. How Epstein-Barr virus envelope glycoprotein gp350 tricks the CR2? A molecular dynamics study. Journal of Molecular Graphics and Modelling 2022;114:108196. [DOI: 10.1016/j.jmgm.2022.108196] [Reference Citation Analysis]
5 Tanner JE, Hu J, Alfieri C. Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture. Cancers (Basel) 2018;10:E112. [PMID: 29642526 DOI: 10.3390/cancers10040112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol 2008;82:11217-27. [PMID: 18786993 DOI: 10.1128/JVI.01673-08] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
7 Widodo, Pristiwanto B, Rifa'i M, Mustafa I, Huyop FZ. A single epitope of Epstein-Barr Virus stimulate IgG production in mice. Ann Med Surg (Lond) 2018;35:55-8. [PMID: 30294429 DOI: 10.1016/j.amsu.2018.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zhao B, Zhang X, Krummenacher C, Song S, Gao L, Zhang H, Xu M, Feng L, Feng Q, Zeng M, Xu Y, Zeng Y. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model. Front Immunol 2018;9:932. [PMID: 29765376 DOI: 10.3389/fimmu.2018.00932] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
9 Weiss ER, Alter G, Ogembo JG, Henderson JL, Tabak B, Bakiş Y, Somasundaran M, Garber M, Selin L, Luzuriaga K. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis. J Virol 2017;91:e01562-16. [PMID: 27733645 DOI: 10.1128/JVI.01562-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
10 Mutsvunguma LZ, Rodriguez E, Escalante GM, Muniraju M, Williams JC, Warden C, Qin H, Wang J, Wu X, Barasa A, Mulama DH, Mwangi W, Ogembo JG. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes. Virology 2019;536:1-15. [PMID: 31377598 DOI: 10.1016/j.virol.2019.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Kawaguchi A, Kanai K, Satoh Y, Touge C, Nagata K, Sairenji T, Inoue Y. The evolution of Epstein-Barr virus inferred from the conservation and mutation of the virus glycoprotein gp350/220 gene. Virus Genes 2009;38:215-23. [PMID: 19153826 DOI: 10.1007/s11262-008-0323-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
12 Tanner JE, Coinçon M, Leblond V, Hu J, Fang JM, Sygusch J, Alfieri C. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule. J Virol 2015;89:4932-41. [PMID: 25694592 DOI: 10.1128/JVI.03269-14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
13 Sitompul LS, Widodo N, Djati MS, Utomo DH. Epitope mapping of gp350/220 conserved domain of epstein barr virus to develop nasopharyngeal carcinoma (npc) vaccine. Bioinformation 2012;8:479-82. [PMID: 22715303 DOI: 10.6026/97320630008479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]